Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

OTTAWA, Ontario, May 30, 2019 /PRNewswire/ -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced their Chief Medical Officer, Ian McGowan MD Ph.D. FRCP, will be presenting at the ASCO meeting which is being held in Chicago (May  31st to June 3, 2019; https://meetings.asco.org/am/attend-meeting). His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients. In his previous position, as a Professor of Medicine at the University of Pittsburgh Medical School, his laboratory undertook research to characterize the prevalence of anal human papillomavirus (HPV) infection in men who have sex with men (MSM) and transgender women. In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa. Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al. Int J STD AIDS 2019).

"Despite increased availability of highly efficacious HPV vaccines, there is a large pool of individuals who have already acquired anal HPV infection and are at risk of developing epithelial dysplasia and in some cases cancer. Unfortunately, this risk is significantly increased when there is co-infection with HIV. These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Orion Biotechnology has an active preclinical program focused on the treatment of gastrointestinal cancers with our lead compound, OB-002, and plans to submit an IND to support Phase 1 clinical trials in 2020.

About Orion Biotechnology Canada, Ltd.

Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company leveraging advanced receptor pharmacology to develop novel therapies for serious chronic illnesses and life-threatening diseases. Since 2017, Orion Biotechnology has been developing a robust pipeline of first-in-class chemokine analogue drug candidates, including our lead candidate, OB-002 – a CCR5 receptor antagonist. Our close ties to diverse institutions and experts around the globe, as well as our proprietary drug discovery platform, continue to stimulate the rapid discovery of promising new treatments. Learn more at www.orionbiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking information, which reflects Orion's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Ross MacLeod
Orion Biotechnology
Canada Ltd
Phone: +1.343.291.1032
[email protected]

Related Images

ian-mcgowan.jpg
Ian McGowan
Orion Biotechnology's CMO

Related Links

Orion Biotechnology Events

SOURCE Orion Biotechnology Canada